VA
HRMY icon

Verdad Advisers’s Harmony Biosciences HRMY Stock Holding History

Verdad Advisers’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Buy
+8,604
New +$271K 0.3% 114

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdad Advisers's HRMY Position: Q2 2026 in Review

Verdad Advisers opened a new position in Harmony Biosciences (HRMY) in Q2 2026: 8,604 shares worth $313K. The stake represents 0.3% of the portfolio and ranks #114 among its holdings.

326 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Verdad Advisers held 8,604 shares of Harmony Biosciences worth $313K as of Q2 2026.
  • Harmony Biosciences was a new Verdad Advisers position in Q2 2026.
  • Harmony Biosciences made up 0.3% of Verdad Advisers's portfolio in Q2 2026, its #114 holding.
  • 326 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.